Recent False Claims Act Cases in the Health Care Industry: Key Takeaways for Providers
False Claims Act Cases (FCA) remain one of the government’s most powerful health care enforcement tools. Recent matters illustrate its broad reach and continuing implications for providers, payors, and suppliers. This client alert highlights notable developments and practical steps organizations can take to mitigate risk.
Over the past year, courts and the Department of Justice (DOJ) have continued to pursue False Claims Act Cases involving improper billing, kickback arrangements, and misrepresentations about services provided. Recent settlements involving hospitals, outpatient providers, and pharmaceutical companies underscore the continuing risk for organizations that seek reimbursement from federal health care programs.
Recent Case False Claims Act Cases Highlights
- Kickbacks and Referral Schemes: A major hospital system recently resolved allegations that it provided unlawful financial incentives to physicians in exchange for patient referrals. The alleged arrangements included disguised consulting agreements and excessive compensation for limited services, raising Anti-Kickback Statute concerns. The settlement included a substantial payment and enhanced compliance monitoring.
- Billing for Non-Rendered Services: A large outpatient provider allegedly billed for physical therapy sessions that did not occur. Whistleblower reports and internal audits identified falsified patient records and claims for services that were not provided or were performed by unqualified staff. The matter resulted in significant penalties and a corporate integrity agreement.
- Pharmaceutical Pricing and Marketing: Recent pharmaceutical FCA matters have targeted alleged inflation of drug prices reported to government programs and promotion of medications for unapproved uses. In one matter, a drug manufacturer allegedly misreported Medicaid rebate data and incentivized sales representatives to promote off-label uses, contributing to a significant settlement.
Legal Trends and Enforcement PrioritiesReflected in False Claims Act Cases
Whistleblower (qui tam) actions remain a key driver of FCA enforcement and a significant source of fraud allegations. Although courts continue to scrutinize whether alleged false claims are material under recent Supreme Court guidance, DOJ enforcement remains active and aggressive.
The FCA’s incentive structure helps explain the continued volume of qui tam activity. Private relators may bring claims on the government’s behalf and, in successful cases, receive a share of the government’s recovery. Relators may also benefit from statutory anti-retaliation protections, while treble damages and civil penalties create substantial settlement pressure for defendants.
Practical Guidance for Health Care Clients
- Strengthen compliance policies governing billing, referral relationships, and service documentation.
- Train personnel on FCA risks, reporting obligations, and whistleblower protections.
- Use periodic audits to identify, investigate, and remediate potential FCA exposure.
- Respond promptly to government inquiries and preserve relevant records.
Given the continued pace of FCA enforcement, health care organizations should take a proactive, well-documented approach to compliance. For assistance evaluating FCA risk or strengthening compliance strategies, please contact our health care law team.
Conclusion
Recent FCA activity confirms that health care providers remain a central focus of federal enforcement, particularly where billing practices, referral relationships, documentation, and pharmaceutical reporting are at issue. Organizations that invest in strong compliance controls, timely internal review, and clear reporting channels will be better positioned to identify risk early and respond effectively when concerns arise.
Stark Law, Anti- Kickback Statute, M S O Structures, Telehealth, Physician Compensation, and Ancillary Services Recent False Claims Act Cases in the Health Care Industry: Key Takeaways for Providers Navigating False Claims Act Liability and Damages— The Importance of Compliance Programs for Healthcare Providers F D A Guidelines on A I Technologies in Medical Devices Agency Law Considerations for A I in Healthcare